HEC Pharm's controlling shareholder proposes buyback of up to 1.2 billion yuan in shares

CLS··CNUS·Read original
2▲6 ▼0Impact / 5
Summary · why it matters

HEC Pharm's controlling shareholder, Shenzhen HEC Industrial, has proposed that the company use its own or self-raised funds to repurchase A-shares, with the buyback amount set at no less than 600 million yuan and no more than 1.2 billion yuan. The repurchase price will not exceed 150% of the average trading price of the stock over the 30 trading days prior to the board resolution, and the implementation period is within six months after board approval. In an after-hours announcement the same day, Shandong Gold Mining's chairman Wang Chenglong proposed a buyback of 300 million to 400 million yuan worth of A-shares, all of which will be cancelled to reduce the company's registered capital. SUPCON Technology plans to raise the upper limit of its share repurchase price from no more than 68.53 yuan per share to no more than 133.50 yuan per share, while Huaqin Technology carried out its first buyback of 1.057 million A-shares for 79.6009 million yuan. In equity transactions, Lian Tai Environmental intends to sell 100% equity in Hunan Lian Tai and Shantou Lian Tai for a total of 1.611 billion yuan, and Jin Jiang Hotels plans to acquire an additional 10% stake each in Vienna Hotels and Baisuicun Catering for approximately 811 million yuan to achieve full ownership. In addition, Nhwa Pharmaceutical has granted Somnivera exclusive rights to an investigational innovative drug for sleep disorders, with potential milestone payments of up to 507 million US dollars.

Impact on assets 9

Others▲ · 9 stocks
Shandong Gold Mining Co Ltd
600547
▲ PositiveCapitalrelevance

Chairman Wang Chenglong proposed a 300-400 million yuan A-share buyback to be cancelled, reducing registered capital.

HUAQIN TECHNOLOGY LTD A
603296
▲ PositiveCapitalrelevance

Huaqin Technology carried out its first buyback of 1.057 million A-shares for 79.6 million yuan.

Jiangsu Nhwa Pharmaceutical Co Ltd
002262
▲ PositiveDemandrelevance

Nhwa Pharmaceutical granted Somnivera exclusive rights to an investigational sleep-disorder drug with potential milestone payments up to $507 million.

Off-coverage companies 5

Hunan Liantai Environmental Protection Co., Ltd.Private± Mixed
relevance

Shantou Liantai Water Co., Ltd.Private± Mixed
relevance

Shenzhen Baisuicun Catering Chain Co., Ltd.Private± Mixed
relevance

Somnivera, Inc.Private± Mixed
relevance

Vienna Hotels Co., Ltd.Private± Mixed
relevance

© 2026 MarketIVNews